AQST Earnings & Financial Statements
Aquestive Therapeutics, Inc.
$4.61
-$0.06(-1.28%)
50
Overall
40
Value
60
Tech
52
Quality
Market Cap
$578.61M
Volume
1.60M
52W Range
$2.93 - $7.55
Target Price
$9.22
AQST earnings and financial statements: Aquestive Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
AQST Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $44.55M | $57.56M | $50.58M | $47.68M | $50.83M |
| Cost of revenue | $18.55M | $17.87M | $20.83M | $19.39M | $14.99M |
| Operating income | -$71.05M | -$30.77M | -$15.10M | -$42.07M | -$34.68M |
| EBITDA | -$61.12M | -$21.60M | $1.18M | -$39.58M | -$45.11M |
| Net income | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -$70.54M |
| EPS (diluted) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $160.43M | $101.42M | $57.42M | $57.07M | $61.99M |
| Total liabilities | $194.09M | $161.58M | $163.91M | $175.62M | $144.13M |
| Shareholders’ equity | -$33.66M | -$60.16M | -$106.49M | -$118.55M | -$82.13M |
| Cash and equivalents | - | - | - | - | $28.02M |
| Long-term debt | $31.86M | $37.47M | $32.91M | $38.53M | $53.50M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$52.43M | -$35.76M | -$6.38M | -$9.82M | -$32.98M |
| Capital expenditure | -$562.0K | -$159.0K | -$995.0K | -$2.52M | -$913.0K |
| Free cash flow | -$52.99M | -$35.92M | -$7.38M | -$12.34M | -$33.89M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AQST | $4.61 | -1.3% | 1.60M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aquestive Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW